Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity
Open Access
- 22 September 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 118 (12), 3301-3310
- https://doi.org/10.1182/blood-2011-02-336321
Abstract
CD3+CD56+ cytokine-induced killer (CIK) cells display a potent cytolytic activity. The adhesion molecule lymphocyte function-associated antigen-1 plays a crucial role in binding as well as in cytolytic activity of CIK cells against tumor target cells expressing the corresponding ligands. CIK cells express activating natural killer (NK) receptors, including NKG2D, DNAX accessory molecule-1 (DNAM-1), and low levels of NKp30. Cell signaling not only through TCR/CD3 but also through NKG2D, DNAM-1, and NKp30 leads to CIK cell activation resulting in granule exocytosis, cytokine secretion, and cytotoxicity. Antibody blocking experiments showed that DNAM-1, NKG2D, and NKp30 are involved in the TCR-independent tumor cell recognition and killing. Anti–CMV-specific CIK cells could be expanded in standard CIK cultures and mediate both specific, MHC-restricted recognition and TCR-independent NK-like cytolytic activity against leukemic cell lines or fresh leukemic blasts. Antibody blocking of lymphocyte function-associated antigen-1 and DNAM-1 led to significant reduction of both CTL and NK-cell functions, whereas blocking of NKG2D and NKp30 only inhibited NK-like cytotoxicity. Their dual-effector function suggests that CIK cells, when used in a clinical setting, may control both neoplastic relapses and viral infections, 2 frequently associated complications in patients who received a transplant.Keywords
This publication has 43 references indexed in Scilit:
- The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humansThe Journal of Experimental Medicine, 2009
- Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15The Journal of Experimental Medicine, 2009
- In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activityBlood, 2008
- Ex Vivo Expansion and Prophylactic Infusion of CMV-pp65 Peptide-Specific Cytotoxic T-Lymphocytes following Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2007
- Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapyExperimental Hematology, 2006
- Reprogramming of CTLs into natural killer–like cells in celiac diseaseThe Journal of Experimental Medicine, 2006
- NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptorBlood, 2005
- Analysis of the receptor-ligand interactions in the natural killer–mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)Blood, 2005
- Coordinated Induction by IL15 of a TCR-Independent NKG2D Signaling Pathway Converts CTL into Lymphokine-Activated Killer Cells in Celiac DiseaseImmunity, 2004
- Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICAScience, 1999